ICT 121

Drug Profile

ICT 121

Alternative Names: ICT-121

Latest Information Update: 30 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ImmunoCellular Therapeutics
  • Developer Cedars-Sinai Health System; ImmunoCellular Therapeutics
  • Class Cancer vaccines; Dendritic cell vaccines; Peptide vaccines
  • Mechanism of Action Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Glioblastoma

Most Recent Events

  • 13 Aug 2018 Phase I development is ongoing in USA
  • 28 Jul 2018 No recent reports of development identified for phase-I development in Glioblastoma(Recurrent) in USA (Intradermal, Injection)
  • 17 Nov 2017 ICT 121 is available for licensing as of 17 Nov 2017. www.imuc.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top